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Abstract
Background: Multiple wearable devices for rhythm analysis have been developed
using either photoplethysmography (PPG) or handheld ECG.
Hypothesis: The aim of this survey was to assess impact of these technologies on
physicians' clinical decision-making regarding initiation of diagnostic steps, drug ther-
apy, and invasive strategies.
Methods: The online survey included 10 questions on types of devices, advantages,
and disadvantages of wearable devices as well as case scenarios for patients with
supraventricular arrhythmias and atrial fibrillation (AF).
Results: A total of 417 physicians (median age 37 [IQR 32-43] years) from 42 coun-
tries world-wide completed the survey.
When presented a tracing of a regular tachycardia by a symptomatic patient, most par-
ticipants would trigger further diagnostic steps (90% for single-lead ECG vs 83% for
PPG, P < .001), while a single-lead ECG would be sufficient to perform an invasive EP
study in approximately half of participants (51% vs 22% for PPG, P < .001).
When presented with a single-lead ECG tracing suggesting AF, most participants (90%)
would trigger further diagnostic steps. A symptomatic AF patient would trigger anti-
coagulation treatment to a higher extent as an asymptomatic patient (59% vs 21%,
P < .001). PPG tracingswould only rarely lead to therapeutic steps regardless of symptoms.
Most participants would like scientific society recommendations on the use of wear-
able devices (62%).
Conclusions: Tracings from wearable rhythm devices suggestive of arrhythmias are
most likely to trigger further diagnostic steps, and in the case of PPG recordings
rarely therapeutic interventions. A majority of participants expect these devices to
facilitate diagnostics and arrhythmia screening but fear data overload and expect sci-
entific society recommendations on the use of wearables.
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1 | INTRODUCTION
Wearable devices have rapidly evolved over the last decade allowing
a consumer-driven rhythm analysis on large segments of symptomatic
or healthy individuals.
Devices utilize two methods for heart rhythm analysis—
photoplethysmography (PPG) or ECG (Table 1).1 PPG is based on light
emitting and light sensing diodes that estimate heart rate from changes
in blood volume caused by peripheral pulsations. Commercially available
smartphones provide the technology to record PPG tracings, which is
utilized by third-party applications. Some devices involve automated
algorithms that can detect pulse irregularity and notify the consumer
regarding a possible arrhythmia. Wearable single-lead or multiple lead
ECG use electrodes that can be hand-held or implemented in a wrist-
band or a smartwatch. Health and fitness technology is a rapidly evolving
market showing a doubling in revenue within the past 5 years.2
The aim of this survey was to assess impact of these technologies
on physicians' clinical decision-making regarding initiation of diagnos-
tic steps, drug therapy, and invasive strategies.
2 | METHODS
An online questionnaire was prepared using the EHRA Young EP
infrastructure and distributed to EHRA Young EP members, members
of national electrophysiology (EP) working groups and via social media
platforms (Twitter, Facebook). The questionnaire included baseline
questions on demographics as well as 10 questions on types of
devices, advantages and disadvantages of wearable devices, as well as
gaps in evidence. Three case scenarios for (a) a young patient with
palpitations, (b) symptomatic atrial fibrillation (AF), and
(c) asymptomatic AF were presented to ask for clinical decision-mak-
ing. The full questionnaire is available in Supporting Information.
Questions were classified as nonmandatory. Responses were
excluded if no answer was given at any clinical case scenario or two
responses were submitted by one person. In case of missing data,
pairwise deletion was performed.
Continuous variables are presented as mean ± SD or median
(interquartile range—IQR). Categorical variables are presented as per-
centages and counts. Questions of clinical decision-making were com-
pared using Wilcoxon test for dependent and Mann-Whitney-U test
for independent variables. Consensus between respondents was mea-
sured using the consensus measure “C,” ranging from
0 (no consensus) to 1 (complete consensus).3 A two-sided P-value of
<.05 was considered significant. Statistical analyses were performed
using the SPSS 20.0 (IBM, Armonk, New York) and R 3.6.1 (The R
Foundation, Vienna, Austria).
3 | RESULTS
Four hundred and seventeen participants completed the online survey
from October 1st to December 31st, 2019. Eleven cases were
excluded due to blank input and two cases were excluded due to dou-
ble entry (matching contact details). The remaining 404 cases were
used for the final analysis. Missing data was present in <5% of clinical
scenario questions and <12% of other questions.
Median age was 37 years (IQR 32-43 years). Most participants
were EP specialists (32%), followed by cardiologists or cardiology fel-
lows (18.5% each), EP team leaders (15.5%), electrophysiology fellows
(12.5%), and doctors or researchers of other professions (3%). Median
experience in EP was 5 years (IQR 1-10 years).
Physicians from 42 different countries participated in the survey,
most of them were from Germany, Denmark (15% each), Serbia (14%),
France (7%), Spain and Austria (5% each). Six percent of participants
were from non-European countries.













ECG-based devices Apple Watch Series 4-5 16.5% 31.4% 23.7% 6.2%
Beurer mobile ECG device 5.1% 5.9% 3.8% 75.8%
imPulse 0.3% 1.8% 0.4% 84.4%
Kardia Mobile 20.4% 30.9% 26.9% 38.2%
Kardia Mobile 6L 7.8% 18.4% 15.9% 43.7%
My Diagnostick 4.2% 3.4% 2.9% 74.0%
Zenicor-ECG 4.4% 4.9% 3.8% 72.6%
PPG-based devices Apple Watch 17.9% 21.4% 17.1% 10.1%
CardiioRhythm 2.0% 4.3% 2.8% 71.4%
FibriCheck 4.1% 3.6% 2.8% 75.1%
Fitbit 9.4% 5.8% 4.7% 44.6%
HeartRate 1.8% 2.9% 2.1% 76.4%
Oura Ring 0.3% 0.8% 1.0% 87.2%
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Most of the participants were in a position to take clinical deci-
sions either independently (75%) or under supervision (21%).
3.1 | Device types
Best known and most recommended ECG devices were the Apple
Watch (Apple Inc, Cupertino, California) and Kardia Mobile (AliveCor
Inc, Mountain View, California; Table 1).
Most popular PPG devices were the Apple Watch, followed by
Fitbit (Fitbit Inc, San Francisco, California), Cardiio Rhythm (Cardiio Inc,
Cambridge, Massachusetts), and FibriCheck (Qompium nv, Hasselt, Bel-
gium). The most recommended PPG device was the Apple Watch.
Neither ECG nor PPG devices were reimbursed in the partici-
pants' countries (≤2% each).
3.2 | Interaction between wearable device user
and healthcare team
Most participants would prefer remote transmission of the wearable
device tracing to a specialized center (34%) over direct presentation
F IGURE 1 Lickert-scale on
clinical decision-making in patients
with wearable device rhythm
recordings. Participants would most
likely perform further diagnostic steps
in patients with regular, A, or
irregular, B, tachycardia recordings
and would less likely take other
clinical decisions in asymptomatic
patients, C, Asterisks indicate
significant difference between ECG
and PPG recordings (P < .001)
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to the responsible physician (29%) or physician recommending the
device (18%). Only 9 % would leave interpretation of the tracings to
third parties.
After data is transmitted to the healthcare team, most participants
would prefer that the hospital or clinic nurse (34%), cardiologist (20%),
primary care physician (11%), or cardiac electrophysiologist (6%) con-
tacts the patient. Only 19% would prefer that the patient should
schedule an appointment.
3.3 | Patient-scenarios for clinical decision-making
In a case example of a young patient with palpitations with on/off-
phenomenon presenting a 30 seconds tracing from a wearable device
indicating narrow-complex tachycardia (in a single-lead ECG) or regu-
lar tachycardia (in a PPG tracing), most participants would trigger fur-
ther diagnostic steps (90% in single-lead ECG, C = 0.70, 83% in PPG,
C = 0.74, Figure 1A). For half of the participants (51%), a single-lead
ECG would be sufficient to perform an invasive electrophysiological
study, while only 22% would indicate an invasive electrophysiological
study based on a PPG tracing. Participants would be more reluctant to
start antiarrhythmic drug therapy in this patient (28% for single-lead
ECG, C = 0.55, 9% for PPG, C = 0.67).
In a case example of a patient with palpitations presenting a
30 seconds tracing indicating AF, most participants would trigger fur-
ther diagnostic steps (90% for single-lead ECG, C = 0.72, 86% for PPG,
C = 0.68, Figure 1B). The majority of participants would start anti-
coagulation (if indicated by CHA2DS2-VASc-Score) based on a single-
lead ECG (59%, C = 0.58), but not on a PPG tracing (21%, C = 0.59).
In a case example of an asymptomatic patient presenting a
30 seconds tracing indicating AF, most participants would also trigger
further diagnostic steps (87% for single-lead ECG, C = 0.71, 79% for
PPG, C = 0.68, Figure 1C). Participants would start anticoagulation
(if indicated by CHA2DS2-VASc-Score) in 44% (C = 0.57) based on a
single-lead ECG and only 14% (C = 0.59) based on a PPG tracing. In
the asymptomatic patient case, participants would be reluctant to
start antiarrhythmic drug therapy, perform ablation therapy or re-do-
ablation based on a single-lead ECG and PPG tracing.
In general, participants would more likely take clinical actions
based on a single-lead ECG than on a PPG recording (P < .001 for
every group-wise comparison except further diagnostic steps in symp-
tomatic patients with AF recording [P = 0.08]).
3.4 | Diagnosis of atrial fibrillation based on a
wearable device tracing
When presented a 30-seconds tracing suggesting AF, participants
would most likely diagnose AF from a Holter ECG (95% very likely or
likely) followed by atrial high rate episodes from an implanted device
(83%) or a single-lead ECG (69%). Only 14% would diagnose AF based
on a PPG tracing (Figure 2).
When asked for a cutoff to diagnose AF in a single-lead ECG trac-
ing, 32% would choose 30 seconds, 10% 1 minute, 2% 5 minutes, 10%
30 minutes, 3% 1 hour, 2% 5.5 hours, and 2% 24 hours. One of four
(24.5%) participants would not diagnose AF based on any wearable
device tracing. Participants with experience in EP would more likely
diagnose AF based on Holter ECGs (mean rank 4.62 vs 4.42, P = .006)
and single-lead ECGs (3.83 vs 3.41, P < .001) than other cardiologists.
3.5 | Advantages and disadvantages of wearable
devices
Participants saw the potential of wearable devices mainly in allowing
faster diagnosis while the main concern was data overload (Figure 3).
In addition to a consensus document from the scientific society,
participants would like to see trials comparing sensitivity and
F IGURE 2 Likelihood of
diagnosing atrial fibrillation (AF) based
on a 30s recording from
Photoplethysmography (PPG), single-
lead ECG, atrial high-rate episodes
(AHRE) from implantable devices and
Holter ECG recordings
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specificity of wearable devices (72%) or a review of validated devices
(70%) in order to facilitate clinical decision-making in daily practice.
Most participants saw the need for specific society recommenda-
tions (62%).
4 | DISCUSSION
Over 400 physicians from more than 40 countries participated in the
wEHRAbles project—an initiative of members of EHRA Young
EP. This is the first structured survey addressing knowledge and
acceptance of wearable rhythm devices as well as relevance of PPG
and ECG devices for clinical decision-making.
This survey demonstrates that physicians:
1. know, use and recommend these novel technologies,
2. would rather perform further diagnostics than take clinical deci-
sions based on these recordings,
3. would rather base clinical decisions on single-lead ECG than PPG
recordings,
4. appreciate the devices' potential in facilitating diagnosis and screening,
5. fear data overload, and
6. call for practical guidance.
4.1 | Device types
The wearable ECG devices that participants of our survey labeled as
most known to them, most available, used and recommended to
patients or colleagues are Apple Watch and two AliveCor devices
(Kardia Mobile and Kardia Mobile 6 L). These answers reflect the
number of published scientific papers and the number of patients
included in the studies with these particular devices and current
media coverage.4,5 Besides Apple Watch and Fitbit, PPG-based
devices were generally less popular among participants of our survey.
4.2 | Interaction between user and
healthcare team
Over the past decade, new wearable devices have allowed consumers
instead of providers to take charge of collecting their heart rhythm
data, thereby significantly expanding the amount of information col-
lected on large segments of symptomatic or healthy individuals. In
addition to data storage, deep-learning algorithms are now capable of
distinguishing between sinus rhythm and arrhythmia (primarily AF)
with reasonable accuracy.6,7 The user-driven unselected recording of
different parameters challenges the interaction between the potential
patient and the healthcare team as there is a fear of data-overload
from otherwise healthy people. However, this fear may be over-
estimated as screening for AF with a median time of 117 days with
PPG-based tachogram in the Apple Heart Study only resulted in 0.5%
notification of irregular rhythm.4 The Huawei Study revealed that the
rate of false positive alarms decreased with age, suggesting screening
for AF could benefit at-risk populations.8
When asked how the data from wearable devices should be
shared with the healthcare team, only 9% of the present survey stated
that they wanted a third party like the industry to provide the data.
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However, as a group they were not settled who should receive the
data, illustrating the challenges ahead with regards to current posi-
tions of the various sectors of the healthcare system in heart rhythm
management.
Recently, the Heart Rhythm Society and the Consumer Technol-
ogy Association has launched a joined guidance paper to the users of
wearable technologies, that is, potential arrhythmia patients.9 This is
an important step to ensure appropriate use of wearable technology,
but scientific society guidelines or position papers on wearable heart
rhythm monitoring devices are warranted to help the healthcare
teams tailor their interaction with the wearable device users but also
addressing the established healthcare system's desired requirements
to the wearable device industry.
4.3 | Clinical decision-making in patients with
palpitations
Evaluation of intermittent palpitations and asymptomatic arrhythmias
has long presented an unmet need in cardiology.
12-lead-ECG remains a cornerstone element for the diagnosis.
However, the sporadic and infrequent nature of supraventricular
tachycardias (SVTs) makes it difficult to capture an episode on ambu-
latory monitoring. The 2019 ESC guidelines indicate that mobile
recording devices may be required for the diagnosis of SVT.10 They
specifically highlight that wrist-worn, optically based heart rate moni-
tors are user-friendly, but at the same time require an appropriate val-
idation. Most participants of the present survey would refer their
patients for an invasive EP study based on a single lead ECG tracing.
In a study involving healthy adults, Wang et al reported variable accu-
racy among different wrist-worn monitors, all being less accurate than
a chest strap-based electrode containing monitor.11
Guidelines for the management of AF state that the diagnosis of
AF requires an ECG recording and that episodes of 30s are diagnos-
tic.12 Since AF is associated with increased risk of stroke, other mor-
bidity and mortality, opportunistic screening is recommended in
patients above 65 years or after transient ischemic attack or ischemic
stroke. Methods for AF detection stated in the guidelines are pulse
taking, ECG rhythm strip recordings, continuous ECG monitoring and
interrogation of implanted cardiac devices. An EHRA consensus docu-
ment on screening for AF explicitly states new wearable devices as AF
screening tools.13
Recent studies have shown that AF screening via widely available
wearable single-lead ECGs and PPG tracings is feasible and reason-
able.4,6,13-16 The present survey shows that most physicians would
perform further conventional rhythm diagnostics when confronted
with recordings suggesting AF. Nevertheless, most physicians would
consider a wearable device recording sufficient to start anti-
coagulation. Although sensitivity and specificity of PPG tracings are
comparable to single-lead ECGs, physicians would rather make clinical
decisions based on single-lead ECGs.
When comparing single-lead ECGs and PPG tracings to conven-
tional Holter recordings and AHRE from implanted cardiac devices,
physicians would surprisingly rather diagnose AF based on the latter,
although current consensus documents highlight that important ques-
tions of diagnostic yield and impact of AHRE episodes remain
unanswered.17
Although studies on anticoagulation in patients with AF detected
by wearable devices are still lacking, physicians in this study agree that
anticoagulation should be considered in symptomatic patients when
detected by single-lead ECG. Physicians would be more reluctant to
prescribe anticoagulation in asymptomatic patients, although stroke
risk in patients with AF is not linked to symptoms of AF.12 This finding
highlights that further studies and consensus is required on when and
whom to anticoagulate based on wearable device rhythm recordings.
A new subtype classification of AF may be needed for asymptomatic
patients with AF detected by wearable devices in order to allow spe-
cific recommendations, comparable to device-detected AHRE.
4.4 | Advantages and disadvantages of wearable
devices
The possibility of unlimited monitoring resulting in a faster diagnosis
is one important advantage of wearable devices. It provides the
opportunity to screen large populations. The traditional Holter and
event recorders only monitor the heart rhythm for a limited period of
time, are uncomfortable to wear and require healthcare staff to prop-
erly apply it to the patient. Implantable loop recorders can monitor for
years but require an invasive procedure. Therefore, it is not inconceiv-
able that wearables will lead to a reduced use of the current systems
and therefore may be cost-effective.
Data overload is by far the most important disadvantage. Dealing
with vast amounts of information coming from technology that might
have limited accuracy is a big concern. Especially false positive results
will lead to overdiagnosis, over treatment, and more workload for the
physician.
The other important disadvantage of wearable devices is that this
technology is patient-driven rather than clinician-driven. As shown in
the Apple Hearth Study and the Huawei study a minority of the par-
ticipants were over 64 years of age, and in the case of arrhythmia
detection would rarely indicate a change of therapy. It is a concern
that these technologies mainly reaches the younger, healthier popula-
tion, leading to an overconsumption of healthcare in otherwise
healthy subjects.4
4.5 | Perspectives
It is anticipated that the use of wearable devices will increase from
325 million connected devices in 2016 to 1.1 billion devices by
2021.18 As no proper guidance exists for interpretation of wearable
device recordings, it is expected that this surge of wearable technol-
ogy will most likely disrupt the traditional delivery of healthcare.
There is a lack of scientific data making it difficult to choose the
right device type for the right patient. Trials comparing the diagnostic
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properties of the different wearable technologies and the effect on
outcome are needed.
There will be a demand for reimbursement, not only of the spe-
cific technology, but also of the medical support to process all the
generated data.
4.6 | Limitations
The present survey has limitations attributed to target respondents
and questionnaire design. The survey was mainly spread through the
scientific network of EHRA Young EP and participation was
completely voluntary, therefore being prone to selection bias. Since
the survey was distributed by the EHRA Young EP network and had
relatively young participants more prone to use wearable technolo-
gies, this may reflect a selection bias and needs to be taken into
account when interpreting the data. Furthermore, in the presented
case scenarios, the preformulated answers may not represent all pos-
sible choices that could be made in individual clinical settings.
The current survey focusses on patient-triggered recordings pres-
ented to physicians and does not differentiate between advantages,
disadvantages and availability of different types of wearable devices.
5 | CONCLUSION
Physicians from more than 40 countries are well aware of current
wearable rhythm devices and already use and recommend these novel
technologies. Tracings from wearable rhythm devices suggestive of
arrhythmias are most likely to trigger further diagnostic steps, and in
the case of PPG recordings rarely therapeutic interventions. A major-
ity of participants expect these devices to facilitate diagnostics and
arrhythmia screening but fear data overload and expect scientific soci-
ety recommendations on the use of wearables.
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